This page brings together the Agency's latest information on cancer. It lists:
Onivyde is a cancer medicine that is used to treat a form of pancreatic cancer called metastatic adenocarcinoma of the pancreas. Metastatic means that the cancer has spread to other parts of the body...
This is a summary of the European public assessment report (EPAR) for Ontruzant. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use...
Docetaxel Kabi is a cancer medicine used to treat the following types of cancer: breast cancer. Docetaxel Kabi can be used on its own after other treatments have failed. It can also be used with...
This is a summary of the European public assessment report (EPAR) for Farydak. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It...
Xofigo is a radiopharmaceutical (a medicine containing a radioactive substance) that is used to treat adults with cancer of the prostate (a gland of the male reproductive system). Xofigo is used when...
EMA has recommended that patients should be tested for the lack of the enzyme dihydropyrimidine dehydrogenase (DPD) before starting cancer treatment with fluorouracil given by injection or infusion (drip) or with the related medicines, capecitabine...
EMA’s safety committee (PRAC) has confirmed that Picato (ingenol mebutate), a gel for treating the skin condition actinic keratosis, may increase the risk of skin cancer and concluded that the risks of the medicine outweigh its benefits. The...
PRAC concludes Picato’s risks are greater than its benefits EMA’s safety committee (PRAC) has confirmed that Picato (ingenol mebutate), a gel for treating the skin condition actinic keratosis, may increase the risk of skin cancer and concluded that...
The product information for Tyverb, a breast cancer medicine, will continue to state that no data are available on the effectiveness of Tyverb used together with an aromatase inhibitor compared with trastuzumab used with an aromatase inhibitor in...
Eight new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended eight medicines for approval at its March 2020 meeting. In line with EMA’s measures to limit the spread of COVID-19, the meeting was held virtually. The...
PRAC starts review of certain ifosfamide cancer medicines At its monthly meeting, EMA’s safety committee (PRAC) has started a review of medicines containing ifosfamide to examine whether there is a higher risk of encephalopathy (brain disorder) with...
Update: Due to a number of cancellations of participants, this workshop is postponed to later in...
The aim of the workshop is to investigate the feasibility of using disease registries for cancer...
The innovation and biomarkers in cancer drug development (IBCD) 2018 event will embrace the full...
The third multi-stakeholder Paediatric Strategy Forum, jointly organised by EMA and ACCELERATE will...